Abstract
Protein:protein interactions are becoming increasingly significant as potential drug targets; however, the rational identification of small molecule inhibitors of such interactions remains a challenge. Pharmacophore modelling is a popular tool for virtual screening of compound libraries, and has previously been successfully applied to the discovery of enzymatic inhibitors. However, the application of pharmacophore modelling in the field of protein:protein interaction inhibitors has historically been considered more of a challenge and remains limited. In this review, we explore the interaction mimicry by known inhibitors that originate from in vitro screening, demonstrating the validity of pharmacophore mapping in the generation of queries for virtual screening. We discuss the pharmacophore mapping methods that have been successfully employed in the discovery of first-in-class inhibitors. These successful cases demonstrate the usefulness of a “tool kit” of diverse strategies for application across a range of situations depending on the available structural information.
Keywords: Drug discovery, Pharmacophore modelling, Protein:protein interaction (PPI), Small molecule protein:protein interaction inhibitor (SMPPII), Virtual screening.
Current Topics in Medicinal Chemistry
Title:Protein Interface Pharmacophore Mapping Tools for Small Molecule Protein: Protein Interaction Inhibitor Discovery
Volume: 13 Issue: 9
Author(s): Arnout Voet, Eleanor F. Banwell, Kamlesh K. Sahu, Jonathan G. Heddle and Kam Y. J. Zhang
Affiliation:
Keywords: Drug discovery, Pharmacophore modelling, Protein:protein interaction (PPI), Small molecule protein:protein interaction inhibitor (SMPPII), Virtual screening.
Abstract: Protein:protein interactions are becoming increasingly significant as potential drug targets; however, the rational identification of small molecule inhibitors of such interactions remains a challenge. Pharmacophore modelling is a popular tool for virtual screening of compound libraries, and has previously been successfully applied to the discovery of enzymatic inhibitors. However, the application of pharmacophore modelling in the field of protein:protein interaction inhibitors has historically been considered more of a challenge and remains limited. In this review, we explore the interaction mimicry by known inhibitors that originate from in vitro screening, demonstrating the validity of pharmacophore mapping in the generation of queries for virtual screening. We discuss the pharmacophore mapping methods that have been successfully employed in the discovery of first-in-class inhibitors. These successful cases demonstrate the usefulness of a “tool kit” of diverse strategies for application across a range of situations depending on the available structural information.
Export Options
About this article
Cite this article as:
Voet Arnout, Banwell Eleanor F., Sahu Kamlesh K., Heddle Jonathan G. and Zhang Kam Y. J., Protein Interface Pharmacophore Mapping Tools for Small Molecule Protein: Protein Interaction Inhibitor Discovery, Current Topics in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/1568026611313090003
DOI https://dx.doi.org/10.2174/1568026611313090003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design MicroRNAs as Regulators in Normal Hematopoietic and Leukemia Stem Cells: Current Concepts and Clinical Implications
Current Molecular Medicine Treatment of Pancreatic Cancer with Pharmacological Ascorbate
Current Pharmaceutical Biotechnology Puerarin: A Review on the Pharmacological Activity, Chemical Properties and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Targeted Genome Editing Tools for Disease Modeling and Gene Therapy
Current Gene Therapy Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design Is There a Clinical Future for Spermatogonial Stem Cells?
Current Stem Cell Research & Therapy Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Effect of Visnagin on Altered Steroidogenesis and Spermatogenesis, and Testicular Injury Induced by the Heavy Metal Lead
Combinatorial Chemistry & High Throughput Screening Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Anti-Cancer Agents in Medicinal Chemistry Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors
Clinical Cancer Drugs Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Evaluation of Brazilian Biotechnology Patent Activity from 1975 to 2010
Recent Patents on DNA & Gene Sequences Molecular Analysis of Primary Central Nervous System and Primary Intraocular Lymphomas.
Current Molecular Medicine Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets